Abstract 5604
Background
Treatment resistance in cancer has been linked to a population of tumor cells with self-renewal properties called cancer stem cells (CSCs). The aim of this study was to isolate and characterize CSCs from lung cancer cell lines and tumor tissue from resected non-small cell lung cancer (NSCLC) patients.
Methods
The study was performed on tumor cells from 8 resected NSCLC patients and 12 NSCLC cell lines. Suspension cultures were established for CSC isolation (3D tumorspheres), whereas differentiated tumor cells were cultured under adherent conditions (2D). In vitro differentiation, proliferation and chemotherapy resistance and in vivo tumor initiation capacity were tested. 60 CSC-related genes were evaluated by RTqPCR. Gene expression results were validated at protein level by immunoblot and IF.
Results
8 out of 20 primary NSCLC cultures were successfully established, forming 3D tight spheroids or loose aggregates. Tumorspheres showed proper differentiation capacity, unlimited exponential growth, high resistance to cisplatin, paclitaxel, vinorelbine and pemetrexed, and great tumor initiation potential. Gene expression analysis revealed high variability between cell lines and patient cultures and that 2D cultures were more homogenous than 3D. Tight tumorspheres expressed more ECAD than loose ones. Lung tumorspheres had significantly higher expression of CSC-related genes (ALDH1A1, KLF4, NANOG, CD44, CD90, CDKN1A, JUNB, MDM2), invasion promoters (MMP9, SNAI1, ITGA6), ligands and receptors of Notch (NOTCH1, NOTCH3, DLL4, JAG1) and Wnt components (CTNNB1 and GSK3B) than their corresponding 2D cultures cells. Based on their significant and consistent overexpression in all tumorspheres: CD44, NANOG, CDKN1A, SNAI1, ITGA6 and NOTCH3 were selected to constitute a gene signature. Protein expression analyses showed overexpression of proteins encoded by the gene signature on tumorspheres from ADC patients.
Conclusions
Lung tumorspheres are a useful platform for CSCs characterization. The expression signature proposed could provide the basis for developing novel therapies for the treatment of lung ADC. Supported by grants RD12/0036/0025 from RTICC-FEDER, PI12-02838 and PI15-00753 from ISCIII.
Clinical trial identification
Legal entity responsible for the study
Laboratorio de Oncología Molecular, Fundación de Investigación Hospital General Universitario de Valencia.
Funding
RTICC-FEDER and Instituto de Salud Carlos III.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract